PDS Biotechnology PDSB
NASDAQ PDSB
$0.72 -0.03 (-3.57%)
As of: Sep 30, 2026 · 2:45 PM EDT

PDS Biotechnology (PDSB) Convertible Debt (2018)

Updated

PDS Biotechnology's Convertible Debt came in at $30,000 for Q4 2018.

Analysis

PDS Biotechnology (PDSB) Convertible Debt (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn
10 PDS Biotechnology 41.38 Mn 41.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 30,000.00
API Access

PDS Biotechnology Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=PDSB&period=max&api_key=YOUR_API_KEY